Connecting chemosensitivity, gene expression and disease

Trends in Pharmacological Sciences

Volumn 29, Issue 1, 2008, Pages 1-5

  Covell, David G ^a  

^a Screening Technologies Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BIOLOGICAL MARKER; FLUOROURACIL; MESSENGER RNA;

ARTICLE; CHEMICAL GENETICS; CHEMOSENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; MEDICAL TECHNOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; PHARMACOGENETICS;

EID: 37649018890     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.10.015     Document Type: Article

References (55)

1. Berger A.B., et al. Activity-based protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4 (2004) 371-381
2. Phan J.H., et al. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics. Prog. Brain Res. 158 (2006) 83-108
3. Kiechle F.L., et al. The -omics era and its impact. Arch. Pathol. Lab. Med. 128 (2004) 1337-1345
4. Jay C., et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26 (2007) 293-300
5. Chung C.H., et al. Genomics and proteomics: emerging technologies in clinical cancer research. Crit. Rev. Oncol. Hematol. 61 (2007) 1-25
6. Ioannidis J.P. Why most published research findings are false. PLoS Med. 2 (2005) e124
7. Lamb J. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 7 (2007) 54-60
8. Kamb A., et al. Why is cancer drug discovery so difficult?. Nat. Rev. Drug Discov. 6 (2007) 115-120
9. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715
10. Boyd M.R., and Paull K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel. Res. 34 (1995) 91-109
11. Shoemaker R.H., et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog. Clin. Biol. Res. 276 (1988) 265-286
12. Shoemaker R.H., et al. Application of high-throughput, molecular-targeted screening to anticancer drug discovery. Curr. Top. Med. Chem. 2 (2002) 229-246
13. Paull K.D., et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 81 (1989) 1088-1092
14. Voeller D.M., et al. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. Cancer Chemother. Pharmacol. 45 (2000) 409-416
15. Kohlhagen G., et al. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol. 54 (1998) 50-58
16. Rabow A.A., et al. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J. Med. Chem. 45 (2002) 818-840
17. Huang R., et al. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action. Pharmacogenomics J. 5 (2005) 381-399
18. Huang R., et al. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action. Biochem. Pharmacol. 69 (2005) 1009-1039
19. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6 (2006) 813-823
20. Bussey K.J., et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5 (2006) 853-867
21. Covell D.G., et al. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases. Proteins 59 (2005) 403-433
22. Huang R., et al. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action. J. Med. Chem. 49 (2006) 1964-1979
23. Huang R., et al. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen. Genomics 87 (2006) 315-328
24. Wallqvist A., et al. Drugs aimed at targeting characteristic karyotypic phenotypes of cancer cells. Mol. Cancer Ther. 4 (2005) 1559-1568
25. Wallqvist A., et al. Evaluating chemical structure similarity as an indicator of cellular growth inhibition. J. Chem. Inf. Model. 46 (2006) 430-437
26. Blower P.E., et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6 (2007) 1483-1491
27. Scherf U., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24 (2000) 236-244
28. Gyorffy B., et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 24 (2005) 7542-7551
29. Kawasumi M., and Nghiem P. Chemical genetics: elucidating biological systems with small-molecule compounds. J. Invest. Dermatol. 127 (2007) 1577-1584
30. Darnell R.B. Developing global insight into RNA regulation. Cold Spring Harb. Symp. Quant. Biol. 71 (2006) 321-327
31. Wang Y., et al. Proteomics approach to illustrate drug action mechanisms. Curr. Drug Discov. Technol. 3 (2006) 199-209
32. Burdine L., and Kodadek T. Target identification in chemical genetics: the (often) missing link. Chem. Biol. 11 (2004) 593-597
33. Gangadhar N.M., and Stockwell B.R. Chemical genetic approaches to probing cell death. Curr. Opin. Chem. Biol. 11 (2007) 83-87
34. Thorpe D.S. Forward & reverse chemical genetics using SPOS-based combinatorial chemistry. Comb. Chem. High Throughput Screen. 6 (2003) 623-647
35. Lamb J., et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313 (2006) 1929-1935
36. Rhodes D.R., et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9 (2007) 166-180
37. Parsons A.B., et al. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126 (2006) 611-625
38. MacDonald M.L., et al. Identifying off-target effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2 (2006) 329-337
39. Lorenzi P.L., et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol. Cancer Ther. 5 (2006) 2613-2623
40. Muller G. Medicinal chemistry of target family-directed masterkeys. Drug Discov. Today 8 (2003) 681-691
41. Petsko G.A. Do the math. Genome Biol. 7 (2006) 119
42. Fay N. The role of the informatics framework in early lead discovery. Drug Discov. Today 11 (2006) 1075-1084
43. Wacholder S., et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 96 (2004) 434-442
44. Hsueh H.M., et al. Comparison of methods for estimating the number of true null hypotheses in multiplicity testing. J. Biopharm. Stat. 13 (2003) 675-689
45. Storey J.D., and Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9440-9445
46. Storey J.D., and Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol. Biol. 224 (2003) 149-157
47. Ioannidis J.P. Genetic associations: false or true?. Trends Mol. Med. 9 (2003) 135-138
48. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
49. Futreal P.A., et al. A census of human cancer genes. Nat. Rev. Cancer 4 (2004) 177-183
50. Bock-Axelsen J., et al. Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 13122-13127
51. Ioannidis J.P. Microarrays and molecular research: noise discovery?. Lancet 365 (2005) 454-455
52. Jenssen T.K., and Hovig E. The semantic web and biology. Drug Discov. Today 7 (2002) 992
53. Neumann E.K., and Quan D. BioDash: a semantic web dashboard for drug development. Pac. Symp. Biocomput. 11 (2006) 176-187
54. Wallqvist A., et al. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors. J. Chem. Inf. Model. 47 (2007) 1414-1427
55. Marcus, A.D. (2007) Will sharing ideas advance cancer research? Wall Street Journal 18 September, Vol CCL, No. 66